About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Cnr1tm1Map
targeted mutation 1, Marc Parmentier
MGI:1857736
Summary 6 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Cnr1tm1Map/Cnr1tm1Map B6.129-Cnr1tm1Map MGI:4881749
hm2
Cnr1tm1Map/Cnr1tm1Map involves: 129S1/Sv * 129X1/SvJ MGI:4881723
hm3
Cnr1tm1Map/Cnr1tm1Map involves: 129S1/Sv * 129X1/SvJ * CD-1 MGI:3758422
ht4
Cnr1tm1Map/Cnr1+ involves: 129S1/Sv * 129X1/SvJ * CD-1 MGI:4881724
cx5
Cnr1tm1Map/Cnr1tm1Map
Tg(SOD1*G93A)1Gur/0
involves: 129S1/Sv * 129X1/SvJ * ABH * C57BL/6 * SJL MGI:4881738
cx6
Cnr1tm1Map/Cnr1tm1Map
Tg(HD82Gln)81Gschi/0
involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6 * CD-1 MGI:5052307


Genotype
MGI:4881749
hm1
Allelic
Composition
Cnr1tm1Map/Cnr1tm1Map
Genetic
Background
B6.129-Cnr1tm1Map
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cnr1tm1Map mutation (0 available); any Cnr1 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
taste/olfaction
• mice fail to exhibit the 2-arachidonoyl glycerol sweet enhancing nerve response and increased licking unlike in wild-type mice (J:156514)
• mice fail to exhibit the 2-arachidonoyl glycerol sweet enhancing nerve response and increased licking unlike in wild-type mice (J:156514)

nervous system
• mice fail to exhibit the 2-arachidonoyl glycerol sweet enhancing nerve response unlike in wild-type mice (J:156514)
• mice fail to exhibit the 2-arachidonoyl glycerol sweet enhancing nerve response unlike in wild-type mice (J:156514)




Genotype
MGI:4881723
hm2
Allelic
Composition
Cnr1tm1Map/Cnr1tm1Map
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cnr1tm1Map mutation (0 available); any Cnr1 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• mice exhibit increased motile spermatozoa in the caput compared with wild-type mice (J:123226)
• mice exhibit increased motile spermatozoa in the caput compared with wild-type mice (J:123226)

skeleton
N
• osteoclast and osteoblast numbers are normal (J:105218)
• osteoclast and osteoblast numbers are normal (J:105218)
• ovariectomized mice do not exhibit a decrease in bone mineral density unlike similarly treated wild-type mice (J:105218)
• ovariectomized mice do not exhibit a decrease in bone mineral density unlike similarly treated wild-type mice (J:105218)
• in the spine, spine, and tibial metaphysis (J:105218)
• in the spine, spine, and tibial metaphysis (J:105218)

nervous system
• mice fail to exhibit depolarization-induced suppression of inhibition unlike wild-type mice (J:109305)
• mice fail to exhibit depolarization-induced suppression of inhibition unlike wild-type mice (J:109305)




Genotype
MGI:3758422
hm3
Allelic
Composition
Cnr1tm1Map/Cnr1tm1Map
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cnr1tm1Map mutation (0 available); any Cnr1 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• following middle cerebral artery occlusion (MCA), mice exhibit a 5-fold increase in mortality compared with similarly treated wild-type mice (J:109213)
• following middle cerebral artery occlusion (MCA), mice exhibit a 5-fold increase in mortality compared with similarly treated wild-type mice (J:109213)

behavior/neurological
• unlike in wild-type mice, there is no decrease in horizontal locomotor activity or rectal temperature following treatment with delta9-tetrahydrocannabinol (delta9-THC) (J:52188)
• in an intravenous self-administration model, the number of nose pokes leading to WIN55,212-2 administration are reduced compared to wild-type mice (J:52188)
• unlike in wild-type mice, there is no abstinence when treated with the Cnr1-receptor antagonist SR141.716A following long term exposure to delta-THC (J:52188)
• unlike wild-type mice, there is no hypotensive response to anandamide or WIN55,212-2 (J:52188)
• unlike in wild-type mice, there is no decrease in horizontal locomotor activity or rectal temperature following treatment with delta9-tetrahydrocannabinol (delta9-THC) (J:52188)
• in an intravenous self-administration model, the number of nose pokes leading to WIN55,212-2 administration are reduced compared to wild-type mice (J:52188)
• unlike in wild-type mice, there is no abstinence when treated with the Cnr1-receptor antagonist SR141.716A following long term exposure to delta-THC (J:52188)
• unlike wild-type mice, there is no hypotensive response to anandamide or WIN55,212-2 (J:52188)
• in an intravenous self-administration model, the number of nose pokes leading to morphine administration are reduced compared to wild-type mice (J:52188)
• naloxine-precipitated morphine withdrawal symptoms are decreased compared to in wild-type mice (J:52188)
• in an intravenous self-administration model, the number of nose pokes leading to morphine administration are reduced compared to wild-type mice (J:52188)
• naloxine-precipitated morphine withdrawal symptoms are decreased compared to in wild-type mice (J:52188)
• in response to chronic unpredictable mild stress, mice exhibit increased depressive-like behavior compared with wild-type mice (J:103942)
• in response to chronic unpredictable mild stress, mice exhibit increased depressive-like behavior compared with wild-type mice (J:103942)
• in response to chronic unpredictable mild stress, mice exhibit increased depressive-like behavior compared with wild-type mice (J:103942)
• in response to chronic unpredictable mild stress, mice exhibit increased depressive-like behavior compared with wild-type mice (J:103942)
• in an elevated plus maze, mice spend less time exploring open arms compared with wild-type mice (J:89437)
• however, mice treated with the cannabinoid antagonist SR141716A exhibit a normal reduction in anxiety (J:89437)
• in an elevated plus maze, mice spend less time exploring open arms compared with wild-type mice (J:89437)
• however, mice treated with the cannabinoid antagonist SR141716A exhibit a normal reduction in anxiety (J:89437)
• under high light conditions, mice exhibit increased anxiety-related behavior in an elevated plus maze compared with wild-type mice (J:89722)
• however, behavior in an elevated plus maze under low light conditions is normal (J:89722)
• under high light conditions, mice exhibit increased anxiety-related behavior in an elevated plus maze compared with wild-type mice (J:89722)
• however, behavior in an elevated plus maze under low light conditions is normal (J:89722)
• in a light/dark box (J:103942)
• in a light/dark box (J:103942)
• when newly exposed to the arena, mice exhibit a moderate increase in locomotor activity to 119% of wild-type mice (J:52188)
• mice exhibit increased exploratory behavior under stressful conditions of an open field and in the spontaneous alteration test (58.9+/-2.2 visits to the arms compared to 47.2+/-1.6 visits to the arms for wild-type mice) (J:52188)
• mice exhibit a decrease in spontaneous alternations in a Y maze (53.7+/-1.9% compared to 61.4+/-1.8% for wild-type mice) (J:52188)
• however, the number of entries and time spent in the open arms in an elevated plus maze are normal (J:52188)
• when newly exposed to the arena, mice exhibit a moderate increase in locomotor activity to 119% of wild-type mice (J:52188)
• mice exhibit increased exploratory behavior under stressful conditions of an open field and in the spontaneous alteration test (58.9+/-2.2 visits to the arms compared to 47.2+/-1.6 visits to the arms for wild-type mice) (J:52188)
• mice exhibit a decrease in spontaneous alternations in a Y maze (53.7+/-1.9% compared to 61.4+/-1.8% for wild-type mice) (J:52188)
• however, the number of entries and time spent in the open arms in an elevated plus maze are normal (J:52188)
• time spent exploring an unknown object is increased (5.33+/-1.5 s compared to 0.66+/-0.3 s for wild-type mice) (J:52188)
• time spent exploring an unknown object is increased (5.33+/-1.5 s compared to 0.66+/-0.3 s for wild-type mice) (J:52188)
• in an active avoidance test, mice exhibit increased conditioned responses compared with wild-type mice (J:103942)
• in an active avoidance test, mice exhibit increased conditioned responses compared with wild-type mice (J:103942)
• the dysphoric effect on conditioned place aversion by U-50,488H is not observed in mutant mice (J:52188)
• the dysphoric effect on conditioned place aversion by U-50,488H is not observed in mutant mice (J:52188)
• when newly exposed to the arena, mice exhibit a moderate increase in locomotor activity to 119% of wild-type mice (J:52188)
• however, activity levels are normal after habituation (J:52188)
• when newly exposed to the arena, mice exhibit a moderate increase in locomotor activity to 119% of wild-type mice (J:52188)
• however, activity levels are normal after habituation (J:52188)
• the antinociception effect of delta9-tetrahydrocannabinol (THC) is abolished when mice are subjected to a hot-plate test and strongly reduced when subjected to a tail-immersion test (J:52188)
• however, the antinociceptive effect of morphine and U-50,488H and the tolerance development for morphine are unaltered (J:52188)
• the antinociception effect of delta9-tetrahydrocannabinol (THC) is abolished when mice are subjected to a hot-plate test and strongly reduced when subjected to a tail-immersion test (J:52188)
• however, the antinociceptive effect of morphine and U-50,488H and the tolerance development for morphine are unaltered (J:52188)
• in an unfamiliar cage, mice exhibit decreased social interaction compared with wild-type mice (J:89722)
• in an unfamiliar cage, mice exhibit decreased social interaction compared with wild-type mice (J:89722)
• mice exhibit increased aggression towards other mice in a home cage compared with wild-type mice (J:89722)
• mice exhibit increased aggression towards other mice in a home cage compared with wild-type mice (J:89722)
• in a resident-intruder test (J:103942)
• in a resident-intruder test (J:103942)

nervous system
• lesions induced by NMDA are twice as large as in similarly treated wild-type mice (J:109213)
• lesions induced by NMDA are twice as large as in similarly treated wild-type mice (J:109213)
• neuronal precursor cell proliferation in the dorsal ganglion and subventricular zone (SVZ) is decreased 50% compared to in wild-type mice (J:102006)
• SR141716A increases proliferation in the dorsal ganglion to a greater extent than in similarly treated wild-type mice (J:102006)
• AM251 induces proliferation in the dorsal ganglion and SVZ unlike in similarly treated wild-type mice (J:102006)
• neuronal precursor cell proliferation in the dorsal ganglion and subventricular zone (SVZ) is decreased 50% compared to in wild-type mice (J:102006)
• SR141716A increases proliferation in the dorsal ganglion to a greater extent than in similarly treated wild-type mice (J:102006)
• AM251 induces proliferation in the dorsal ganglion and SVZ unlike in similarly treated wild-type mice (J:102006)
• ollowing middle cerebral artery occlusion (MCA), mice exhibit a 5-fold increase in mortality compared with similarly treated wild-type mice (J:109213)
• ollowing middle cerebral artery occlusion (MCA), mice exhibit a 5-fold increase in mortality compared with similarly treated wild-type mice (J:109213)
• following middle cerebral artery occlusion (MCA) (J:109213)
• following middle cerebral artery occlusion (MCA) (J:109213)

homeostasis/metabolism
• basal and stress-induced (J:89722)
• basal and stress-induced (J:89722)
• slightly but significantly more sensitive to 3NP intoxication (J:172874)
• slightly but significantly more sensitive to 3NP intoxication (J:172874)
• lesions induced by NMDA are twice as large as in similarly treated wild-type mice (J:109213)
• lesions induced by NMDA are twice as large as in similarly treated wild-type mice (J:109213)
• ollowing middle cerebral artery occlusion (MCA), mice exhibit a 5-fold increase in mortality compared with similarly treated wild-type mice (J:109213)
• ollowing middle cerebral artery occlusion (MCA), mice exhibit a 5-fold increase in mortality compared with similarly treated wild-type mice (J:109213)
• following middle cerebral artery occlusion (MCA) (J:109213)
• following middle cerebral artery occlusion (MCA) (J:109213)

integument
• the antinociception effect of delta9-tetrahydrocannabinol (THC) is abolished when mice are subjected to a hot-plate test and strongly reduced when subjected to a tail-immersion test (J:52188)
• however, the antinociceptive effect of morphine and U-50,488H and the tolerance development for morphine are unaltered (J:52188)
• the antinociception effect of delta9-tetrahydrocannabinol (THC) is abolished when mice are subjected to a hot-plate test and strongly reduced when subjected to a tail-immersion test (J:52188)
• however, the antinociceptive effect of morphine and U-50,488H and the tolerance development for morphine are unaltered (J:52188)

cellular
• lesions induced by NMDA are twice as large as in similarly treated wild-type mice (J:109213)
• lesions induced by NMDA are twice as large as in similarly treated wild-type mice (J:109213)
• neuronal precursor cell proliferation in the dorsal ganglion and subventricular zone (SVZ) is decreased 50% compared to in wild-type mice (J:102006)
• SR141716A increases proliferation in the dorsal ganglion to a greater extent than in similarly treated wild-type mice (J:102006)
• AM251 induces proliferation in the dorsal ganglion and SVZ unlike in similarly treated wild-type mice (J:102006)
• neuronal precursor cell proliferation in the dorsal ganglion and subventricular zone (SVZ) is decreased 50% compared to in wild-type mice (J:102006)
• SR141716A increases proliferation in the dorsal ganglion to a greater extent than in similarly treated wild-type mice (J:102006)
• AM251 induces proliferation in the dorsal ganglion and SVZ unlike in similarly treated wild-type mice (J:102006)




Genotype
MGI:4881724
ht4
Allelic
Composition
Cnr1tm1Map/Cnr1+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cnr1tm1Map mutation (0 available); any Cnr1 mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• following middle cerebral artery occlusion (MCA) (J:109213)
• following middle cerebral artery occlusion (MCA) (J:109213)

nervous system
• following middle cerebral artery occlusion (MCA) (J:109213)
• following middle cerebral artery occlusion (MCA) (J:109213)




Genotype
MGI:4881738
cx5
Allelic
Composition
Cnr1tm1Map/Cnr1tm1Map
Tg(SOD1*G93A)1Gur/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * ABH * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cnr1tm1Map mutation (0 available); any Cnr1 mutation (7 available)
Tg(SOD1*G93A)1Gur mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• despite similar disease progression, mice exhibit longer life span compared with Tg(SOD1*G93A)1Gur mice (J:111498)
• despite similar disease progression, mice exhibit longer life span compared with Tg(SOD1*G93A)1Gur mice (J:111498)




Genotype
MGI:5052307
cx6
Allelic
Composition
Cnr1tm1Map/Cnr1tm1Map
Tg(HD82Gln)81Gschi/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6 * CD-1
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cnr1tm1Map mutation (0 available); any Cnr1 mutation (7 available)
Tg(HD82Gln)81Gschi mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• reduced lifespan compared to wild-type controls (J:172874)
• however lifespan is similar to transgenic mice wild-type for Cnr1 (J:172874)
• reduced lifespan compared to wild-type controls (J:172874)
• however lifespan is similar to transgenic mice wild-type for Cnr1 (J:172874)

nervous system
• increase in the density of ubiquitin positive aggregates in the striatum compared to transgenic mice wild-type for Cnr1 (J:172874)
• increase in the density of ubiquitin positive aggregates in the striatum compared to transgenic mice wild-type for Cnr1 (J:172874)

behavior/neurological
• reduced latency to fall and an increased number of falls in a rotarod assay (J:172874)
• motor performance is worse than in transgenic mice wild-type for Cnr1 (J:172874)
• motor performance is worse than in transgenic mice wild-type for Cnr1 (J:172874)
• reduced latency to fall and an increased number of falls in a rotarod assay (J:172874)

growth/size/body
• fail to gain weight after 16 weeks of age (J:172874)
• fail to gain weight after 16 weeks of age (J:172874)
• fail to gain weight after 16 weeks of age (J:172874)
• fail to gain weight after 16 weeks of age (J:172874)

Mouse Models of Human Disease
OMIM ID Ref(s)
Huntington Disease; HD 143100 J:172874





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory